by Primrose Bio | Mar 26, 2025 | Featured, Press
Significantly increased quality and lower manufacturing costs for long template mRNAs San Diego, Calif. March 26, 2025 – Primrose Bio, Inc. (“Primrose”), a company developing proprietary therapeutic manufacturing technologies, announces the launch of Prima RNApols™... 
by Primrose Bio | Mar 20, 2025 | Events
Primrose Bio was proud to participate in Bio-Europe Spring 2025, held March 17–19 in Italy. Representing the team, Alec Tzianabos connected with global partners to discuss our scalable, efficient, and cost-effective manufacturing solutions for complex biologics.... 
by Primrose Bio | Jan 17, 2025 | Events
Primrose Bio kicked off the year at JPM Week 2025 in San Francisco, where our executive team — Helge Zieler (CEO), Simon Latimer (CFO), Michele Rubino (CBO), and Louis J. Cantolupo (VP of Business Development) — met with partners, investors, and biotech... 
by Primrose Bio | Jan 10, 2025 | Featured, Press
Primrose Bio, Inc. (“Primrose”), a company with proprietary manufacturing technologies for human therapeutics, and Serum Institute of India Pvt. Ltd. (“SIIPL”), the world’s largest vaccine manufacturer, today announced a collaboration to develop a novel multi-antigen... 
by Primrose Bio | Sep 3, 2024 | Featured, Press
Primrose Bio, a leading biotechnology company specializing in technologies that improve the manufacturing of next-generation therapeutics, and ExPLoRNA Therapeutics, a pioneering biotechnology company advancing mRNA technologies, vaccines, and therapeutics, announced...